DiaMedica Therapeutics In... (DMAC)
NASDAQ: DMAC
· Real-Time Price · USD
6.14
0.77 (14.34%)
At close: Sep 05, 2025, 3:59 PM
6.12
-0.33%
After-hours: Sep 05, 2025, 07:34 PM EDT
14.34% (1D)
| Bid | 5.61 |
| Market Cap | 317.37M |
| Revenue (ttm) | 13.8M |
| Net Income (ttm) | -29.58M |
| EPS (ttm) | -0.7 |
| PE Ratio (ttm) | -8.77 |
| Forward PE | -7.26 |
| Analyst | Strong Buy |
| Ask | 6.48 |
| Volume | 739,370 |
| Avg. Volume (20D) | 350,088 |
| Open | 5.58 |
| Previous Close | 5.37 |
| Day's Range | 5.50 - 6.20 |
| 52-Week Range | 3.19 - 6.82 |
| Beta | 1.40 |
About DMAC
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol DMAC
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for DMAC stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts5 months ago
-13.02%
DiaMedica Therapeutics shares are trading lower fo...
Unlock content with
Pro Subscription
3 weeks ago · seekingalpha.com
DiaMedica Therapeutics Inc. (DMAC) Q2 2025 Earnings Call TranscriptDiaMedica Therapeutics Inc. (NASDAQ:DMAC ) Q2 2025 Earnings Conference Call August 13, 2025 8:00 AM ET Company Participants Dietrich John Pauls - President, CEO & Director Julie Krop - Chief Medical O...
1 month ago · businesswire.com
DiaMedica Therapeutics Announces Closing of $30.1 Million Private PlacementMINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction a...
